NCT06568939

AUG 14, 2026 · PHASE 2 TRIAL

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov

This is an active Phase 2 trial registration with no results reported; the study is designed to assess safety and efficacy of telisotuzumab vedotin in previously treated NSCLC but enrollment and follow-up are ongoing.